Sun Pharmaceutical Industries Ltd
NSE: SUNPHARMA · ISIN INE044A01036
₹1,794.30
+38.90 (+2.22%)up today
SUNPHARMA at a glance
Sun Pharmaceutical is India's largest pharmaceutical company by revenue, with a growing specialty franchise in dermatology and ophthalmology. In this sample dataset it trades at ₹1,794.30 on a trailing P/E of 35.2 with promoter holding of 54.5%.
Price history
Last 60 sessionsTrading at 78% of its 52-week range
Key statistics
- Market cap
- ₹430500Cr
- P/E (TTM)
- 35.2
- P/B ratio
- 5.60
- Book value
- ₹320
- EPS (TTM)
- ₹51.00
- Dividend yield
- 0.78%
- Day range
- ₹1,748 – ₹1,803
- Volume
- 32,18,900
Trailing twelve months
Per share
Shares traded
Fundamental metrics
Pharmaceuticals & Specialty| Metric | Value | What it measures |
|---|---|---|
| Return on equity (ROE) | 16.9% | Net profit as a share of shareholders' equity |
| Return on capital employed (ROCE) | 19.4% | Operating profit against total capital employed |
| Debt to equity | 0.04 | Borrowings below equity |
| Promoter holding | 54.5% | As per latest disclosed shareholding pattern |
| Promoter pledge | 0.0% | No pledged promoter shares disclosed |
| Face value | ₹1 | Per share |
Ratios are computed from reported financials. They describe past performance and do not indicate future results.
Forecast scenarios
Multi-year Bull, Base and Bear scenarios for SUNPHARMA are shown here only when sourced from a named third-party consensus provider, with the date of that estimate.
GrowIQ Capital does not publish its own price targets. Issuing price targets or research recommendations on listed securities requires registration as a Research Analyst under the SEBI (Research Analysts) Regulations, 2014, which this entity does not hold.
To enable this panel, wire a licensed consensus feed into consensus.source in lib/market-data.ts. Reproducing a provider's estimates also requires the right to redistribute them.
Regulatory & overhang radar
Structural factors that materially influence this business. Descriptive context, not a view on the stock.
US FDA facility inspections
Export revenue depends on manufacturing facilities clearing regulatory inspections. Observations or import alerts on a key plant can affect the earnings outlook for that site's products.
Information only. GrowIQ Capital provides financial data analytics, market information and educational content. We are not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this platform constitutes investment advice or a recommendation to buy or sell any security. Nothing on this page is a recommendation to buy, sell, or hold Sun Pharmaceutical Industries Ltd. Investments in securities markets are subject to market risks. Read all the related documents carefully before investing. Past performance is not indicative of future returns and does not guarantee future results.